Tvardi Therapeutics (NASDAQ:TVRD) Upgraded to Strong-Buy at Lucid Cap Mkts

Tvardi Therapeutics (NASDAQ:TVRD) was upgraded by research analysts at Lucid Cap Mkts from a “hold” rating to a “strong-buy” rating in a report issued on Wednesday,Zacks.com reports.

A number of other research firms have also recently weighed in on TVRD. Raymond James Financial cut Tvardi Therapeutics from an “outperform” rating to a “market perform” rating in a report on Tuesday, October 14th. Wall Street Zen lowered Tvardi Therapeutics from a “hold” rating to a “sell” rating in a report on Friday, January 23rd. BTIG Research dropped their price target on Tvardi Therapeutics from $55.00 to $15.00 and set a “buy” rating for the company in a research report on Monday, October 13th. Piper Sandler lowered shares of Tvardi Therapeutics from an “overweight” rating to a “neutral” rating in a research report on Monday, October 13th. Finally, Weiss Ratings reissued a “sell (e)” rating on shares of Tvardi Therapeutics in a research note on Monday, December 29th. One investment analyst has rated the stock with a Strong Buy rating, three have issued a Buy rating, three have assigned a Hold rating and one has issued a Sell rating to the company’s stock. Based on data from MarketBeat, the company currently has an average rating of “Moderate Buy” and a consensus target price of $55.50.

Tvardi Therapeutics Stock Performance

Shares of NASDAQ TVRD opened at $3.86 on Wednesday. Tvardi Therapeutics has a one year low of $3.74 and a one year high of $43.65. The firm has a market capitalization of $36.21 million, a P/E ratio of -0.40 and a beta of 0.14. The company’s fifty day moving average is $4.22 and its two-hundred day moving average is $15.61.

Tvardi Therapeutics (NASDAQ:TVRD) last announced its quarterly earnings data on Thursday, November 13th. The company reported ($0.59) EPS for the quarter, beating the consensus estimate of ($0.83) by $0.24.

Institutional Inflows and Outflows

Several institutional investors have recently bought and sold shares of the business. JPMorgan Chase & Co. purchased a new stake in shares of Tvardi Therapeutics in the second quarter valued at $39,000. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. purchased a new position in Tvardi Therapeutics during the second quarter worth about $43,000. Headlands Technologies LLC purchased a new stake in Tvardi Therapeutics in the 2nd quarter valued at about $80,000. New York State Common Retirement Fund purchased a new stake in Tvardi Therapeutics in the 2nd quarter valued at about $92,000. Finally, Squarepoint Ops LLC acquired a new position in shares of Tvardi Therapeutics during the 3rd quarter valued at about $318,000. 44.66% of the stock is currently owned by institutional investors and hedge funds.

Tvardi Therapeutics Company Profile

Cara Therapeutics, Inc, an early commercial-stage biopharmaceutical company, focuses on developing and commercializing chemical entities with a primary focus on pruritus and pain by selectively targeting kappa opioid receptors in the United States. The company is developing product candidates that target the body’s peripheral nervous system and immune cells. The company’s lead product is KORSUVA (difelikefalin) injection for the treatment of moderate-to-severe pruritus associated with chronic kidney disease (CKD) in adults undergoing hemodialysis.